BRCA1 and breast cancer: The efficacy of PARPi therapy was initially demonstrated in high-grade serous ovarian cancer (referred to as OV hereafter) and breast cancer (BC), in which HRD was driven by germline pathogenic variants in either the BRCA1 or BRCA2 genes (2).